Heather Rutter
University of Oxford(GB)
Publications by Year
Research Areas
Mobile Health and mHealth Applications, Chronic Obstructive Pulmonary Disease (COPD) Research, Blood Pressure and Hypertension Studies, Non-Invasive Vital Sign Monitoring, Digital Mental Health Interventions
Most-Cited Works
- → Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial(2018)407 cited
- → Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial(2022)395 cited
- → Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study(2020)155 cited
- → Self-Management Support Using a Digital Health System Compared With Usual Care for Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial(2017)144 cited
- → Digital health system for personalised COPD long-term management(2017)110 cited
- → Using a mobile health application to support self-management in chronic obstructive pulmonary disease: a six-month cohort study(2015)104 cited
- → Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial(2022)51 cited
- → Self-management support using an Internet-linked tablet computer (the EDGE platform)-based intervention in chronic obstructive pulmonary disease: protocol for the EDGE-COPD randomised controlled trial(2014)36 cited
- → Effect of Probiotic Use on Antibiotic Administration Among Care Home Residents(2020)32 cited
- → Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk(2021)28 cited